Clinical Trial Update: 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cladribine (2-Chlorodeoxyadenosine) in combination with cytarabine for idiopathic hypereosinophilic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome
• Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Cladribine (cladribine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED